Trials / Completed
CompletedNCT01047267
Pharmacokinetics of Anidulafungin on Intensive Care Unit (ICU)
Pharmacokinetics of Anidulafungin in Critically Ill Patients With Invasive Candidiasis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (actual)
- Sponsor
- University Medical Center Groningen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to determine whether pharmacokinetic parameters of anidulafungin correlate with disease severity and plasma protein levels in critically ill patients.
Detailed description
One of the risk factors for mortality of patients with candidemia is inadequate antifungal therapy. The first days in the intensive care unit (ICU), patients are unstable and it can be questioned whether therapeutic levels of anidulafungin are reached after a standard loading scheme. At this moment there are several clues that the PK of anidulafungin in critically ill patients is different, but an overall picture is lacking. For the investigation of the correlation of the pharmacokinetics of anidulafungin and the disease severity a full pharmacokinetic profile will be obtained. Predictive scoring systems will be used to assess disease severity.
Conditions
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2011-11-01
- Completion
- 2011-12-01
- First posted
- 2010-01-12
- Last updated
- 2012-04-06
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT01047267. Inclusion in this directory is not an endorsement.